165 related articles for article (PubMed ID: 35585116)
1. Long-term clinical course and progression of lymphangioleiomyomatosis in a single lung transplant referral centre in Korea.
Chang S; Choi JS; Leem AY; Lee SH; Lee SH; Kim SY; Chung KS; Jung JY; Kang YA; Kim YS; Lee JG; Paik HC; Shim HS; Lee EH; Park MS
Sci Rep; 2022 May; 12(1):8260. PubMed ID: 35585116
[TBL] [Abstract][Full Text] [Related]
2. Experience of Lung Transplantation in Patients with Lymphangioleiomyomatosis at a Brazilian Reference Centre.
Baldi BG; Samano MN; Campos SV; de Oliveira MR; Junior JEA; Carraro RM; Teixeira RHOB; Minguini IP; Burlina R; Pato EZS; Carvalho CRR; Costa AN
Lung; 2017 Dec; 195(6):699-705. PubMed ID: 28823029
[TBL] [Abstract][Full Text] [Related]
3. Predicting Individualized Lung Disease Progression in Treatment-Naive Patients With Lymphangioleiomyomatosis.
Palipana AK; Gecili E; Song S; Johnson SR; Szczesniak RD; Gupta N
Chest; 2023 Jun; 163(6):1458-1470. PubMed ID: 36610667
[TBL] [Abstract][Full Text] [Related]
4. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation?
El-Chemaly S; Goldberg HJ; Glanville AR
Expert Rev Respir Med; 2014 Dec; 8(6):657-60. PubMed ID: 25199529
[TBL] [Abstract][Full Text] [Related]
5. Long-term results of sirolimus treatment in lymphangioleiomyomatosis: a single referral centre experience.
Revilla-López E; Berastegui C; Méndez A; Sáez-Giménez B; Ruiz de Miguel V; López-Meseguer M; Monforte V; Bravo C; Pujana MA; Ramon MA; Gómez-Ollés S; Roman A;
Sci Rep; 2021 May; 11(1):10171. PubMed ID: 33986388
[TBL] [Abstract][Full Text] [Related]
6. Long-term clinical course and outcomes in patients with lymphangioleiomyomatosis.
Yoon HY; Kim HJ; Song JW
Respir Res; 2022 Jun; 23(1):158. PubMed ID: 35717210
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of sirolimus in lymphangioleiomyomatosis.
McCormack FX; Inoue Y; Moss J; Singer LG; Strange C; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Young LR; Kinder BW; Downey GP; Sullivan EJ; Colby TV; McKay RT; Cohen MM; Korbee L; Taveira-DaSilva AM; Lee HS; Krischer JP; Trapnell BC; ;
N Engl J Med; 2011 Apr; 364(17):1595-606. PubMed ID: 21410393
[TBL] [Abstract][Full Text] [Related]
8. Rates of change in FEV
Taveira-DaSilva AM; Julien-Williams P; Jones AM; Stylianou M; Moss J
Eur Respir J; 2018 Apr; 51(4):. PubMed ID: 29519926
[TBL] [Abstract][Full Text] [Related]
9. Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?
Neurohr C; Hoffmann AL; Huppmann P; Herrera VA; Ihle F; Leuschner S; von Wulffen W; Meis T; Baezner C; Leuchte H; Baumgartner R; Zimmermann G; Behr J
Respir Res; 2011 May; 12(1):66. PubMed ID: 21600034
[TBL] [Abstract][Full Text] [Related]
10. Lymphangioleiomyomatosis.
Doubková M; Štefániková M; Čan V; Merta Z; Svoboda M
Klin Onkol; 2019; 32(5):367-374. PubMed ID: 31610670
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the MILES cohort reveals determinants of disease progression and treatment response in lymphangioleiomyomatosis.
Gupta N; Lee HS; Young LR; Strange C; Moss J; Singer LG; Nakata K; Barker AF; Chapman JT; Brantly ML; Stocks JM; Brown KK; Lynch JP; Goldberg HJ; Downey GP; Taveira-DaSilva AM; Krischer JP; Setchell K; Trapnell BC; Inoue Y; McCormack FX;
Eur Respir J; 2019 Apr; 53(4):. PubMed ID: 30846465
[TBL] [Abstract][Full Text] [Related]
12. A survey of use of mTOR inhibitors in patients with lymphangioleiomyomatosis listed for lung transplant.
Warrior K; Leard LE; Nair AR; Gries CJ; Fisher AJ; Johnson SR; McCormack FX; Dilling DF
Respir Med; 2022; 195():106779. PubMed ID: 35276437
[TBL] [Abstract][Full Text] [Related]
13. Mayo clinic experience of lung transplantation in pulmonary lymphangioleiomyomatosis.
Ussavarungsi K; Hu X; Scott JP; Erasmus DB; Mallea JM; Alvarez F; Lee AS; Keller CA; Ryu JH; Burger CD
Respir Med; 2015 Oct; 109(10):1354-9. PubMed ID: 26321137
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis.
Yoon HY; Hwang JJ; Kim DS; Song JW
Orphanet J Rare Dis; 2018 Nov; 13(1):204. PubMed ID: 30428897
[TBL] [Abstract][Full Text] [Related]
15. [Lung transplantation in sporadic lymphangioleiomyomatosis: study of 7 cases].
Ansótegui Barrera E; Mancheño Franch N; Peñalver Cuesta JC; Vera-Sempere F; Padilla Alarcón J
Med Clin (Barc); 2013 Oct; 141(8):349-52. PubMed ID: 23937818
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Effect of Sirolimus for Lymphangioleiomyomatosis Remaining in the Abdominopelvic Region After Lung Transplantation: A Case Report.
Ito T; Suno M; Sakamoto K; Yoshizaki Y; Yamamoto K; Nakanishi R; Hirano Y; Irie M; Kurosaki T; Otani S; Yamane M; Sugimoto S; Miyoshi K; Oto T
Transplant Proc; 2016; 48(1):271-4. PubMed ID: 26915883
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus for lymphangioleiomyomatosis lesions.
Egan JJ; Remund KF; Corris P
N Engl J Med; 2008 May; 358(18):1963-4; author reply 1964. PubMed ID: 18450609
[No Abstract] [Full Text] [Related]
18. Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis.
Yao J; Taveira-DaSilva AM; Jones AM; Julien-Williams P; Stylianou M; Moss J
Am J Respir Crit Care Med; 2014 Dec; 190(11):1273-82. PubMed ID: 25329516
[TBL] [Abstract][Full Text] [Related]
19. Effects of sirolimus in lymphangioleiomyomatosis patients on lung cysts and pulmonary function: long-term follow-up observational study.
Kim C; Do KH; Cha J; Song JW; Lee SM; Lee KY
Eur Radiol; 2020 Feb; 30(2):735-743. PubMed ID: 31471750
[TBL] [Abstract][Full Text] [Related]
20. Favorable survival even with high disease-specific complication rates in lymphangioleiomyomatosis after lung transplantation-long-term follow-up of a Japanese center.
Kurosaki T; Otani S; Miyoshi K; Okazaki M; Sugimoto S; Suno M; Yamane M; Kobayashi M; Oto T; Toyooka S
Clin Respir J; 2020 Feb; 14(2):116-123. PubMed ID: 31729820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]